



Pressrelease February 9, 2009

GENOVIS: 90,5 % OF THE NEW SHARE ISSUE WAS SUBSCRIBED

Genovis AB (publ) has carried out its earlier published new share issue with preferential rights to existing shareholders.

Of the total amount subscribed in the new share issue 79,5 % was subscribed by existing shareholders and with preferential rights. The rest of the shares were subscribed without preferential rights within the frame of the highest amount of the issuing. The issuing ensures Genovis approximately 9,8 MSEK before issue expenses. The number of shares increased from 10,886,233 to 14,172,066.

Contract note and notification of allotment of shares subscribed without subscription rights is estimated to be sent out around February 10, 2009.

For more information, contact:
Sarah Fredriksson, CEO, Genovis AB
+46-46-10 12 30
sarah.fredriksson@genovis.com

Genovis is a biotech company on the leading edge of nanotechnology and nanoparticles. The company's patented nano-induced magnetic transfer (NIMT®) technology was developed to facilitate effective preclinical research for the life science industry. Genovis shares are listed on the First North OMX Nordic Exchange. Mangold Fondkommission is our certified advisor and liquidity guarantor.